BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10147740)

  • 1. Perspectives in marrow graft T-cell depletion in allogeneic matched related bone marrow transplantation.
    Tiberghien P; Hervé P
    Transfus Sci; 1992; 13(4):443-54. PubMed ID: 10147740
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell depletion in allogeneic bone marrow transplantation for acute leukaemias.
    Aversa F; Terenzi A; Carotti A; Velardi A; Latini P; Gambelunghe C; Grignani F; Martelli MF
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():69-72. PubMed ID: 2697440
    [No Abstract]   [Full Text] [Related]  

  • 5. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [T cell depletion for allogeneic bone marrow transplantation].
    Morishima Y
    Nihon Rinsho; 1990 Sep; 48(9):1971-6. PubMed ID: 2232199
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias.
    Bunin N; Aplenc R; Leahey A; Magira E; Grupp S; Pierson G; Monos D
    Bone Marrow Transplant; 2005 Jan; 35(2):151-8. PubMed ID: 15531896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
    Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
    Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
    [No Abstract]   [Full Text] [Related]  

  • 11. Mixed chimerism after allogeneic bone marrow transplantation for leukemias.
    Bertheas MF; Lafage M; Blaise D; Stoppa AM; Viens P; Mannoni P; Maraninchi D
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():61-3. PubMed ID: 2390641
    [No Abstract]   [Full Text] [Related]  

  • 12. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
    Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
    Hummel S; Wilms D; Vitacolonna M; Zöller M
    J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
    de Witte T; Preijers F; Schattenberg A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
    [No Abstract]   [Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
    Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ
    Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell depletion in bone marrow transplantation for leukemia: current results and future directions.
    Butturini A; Gale RP
    Bone Marrow Transplant; 1988 May; 3(3):185-92. PubMed ID: 3048485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P; Flesch M
    Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.